INHERENT SENSITIVITY OF CULTURED HUMAN EMBRYONAL CARCINOMA-CELLS TO ADDUCTS OF CIS-DIAMMINEDICHLOROPLATINUM(II) ON DNA

  • 15 December 1987
    • journal article
    • research article
    • Vol. 47  (24) , 6810-6813
Abstract
Clinical and experimental data indicate that human embryonal carcinoma cells are unusually sensitive to the antitumor drug cis-diammine-dichloroplatinum(II) (cisplatin), but the basis of this sensitivity is unknown. Using colony formation assays we measured survival of cultured human embryonal carcinoma cells following cisplatin treatment and related survival to the amount of platinum bound to DNA, determined by isolation of cellular DNA and flameless atomic absorption spectrometry, over a range of drug doses. Similar measurements were carried out on F9 mouse embryonal carcinoma cells and on a fibroblast cell strain from a patient with the genetic disease Fanconi''s anemia, a syndrome associated with hypersensitivity to cytotoxic and clastogenic effects of difunctional DNA-binding agents. These results were compared with similar analyses on a variety of cultured cells from previous studies. The embryonal carcinoma cells and the Fanconi''s anemia fibroblast strain were among the most sensitive cells on a dose-response basis. Since the amount of platinum bound to DNA after treatment of these cells was similar to values reported for many other cell types, it follows that mouse and human embryonal carcinoma cells are inherently sensitive to DNA-bound platinum adducts, to a degree approaching the sensitivity of fibroblasts from patients with xeroderma pigmentosum and Fanconi''s anemia.

This publication has 11 references indexed in Scilit: